Naftidrofuryl
Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized).[1][2][3] Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.
 | |
| Clinical data | |
|---|---|
| Trade names | Praxilene |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Elimination half-life | 1 - 3.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.045.960  |
| Chemical and physical data | |
| Formula | C24H33NO3 |
| Molar mass | 383.532 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.
Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[4]
Naftidrofuryl may be effective for relieving the pain of muscle cramps.[5]
Adverse Effects
Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.[6]
See also
References
- Peter Lanzer; Eric J. Topol (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9.
- I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN 978-94-011-4439-1.
- Aly, Saida Abdel Regal; Hossain, Murad; Bhuiyan, Mohiuddin Ahmed; Nakamura, Takashi; Nagatomo, Takafumi (2009). "Assessment of Binding Affinity to 5-Hydroxytryptamine 2A (5-HT2A) Receptor and Inverse Agonist Activity of Naftidrofuryl: Comparison With Those of Sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–450. doi:10.1254/jphs.09124FP. ISSN 1347-8613.
- "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". www.der-arzneimittelbrief.de.
- Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.
- Brayfield, A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.